Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Sara Scarlet, MD and Selwyn O. Rogers, Jr., MD, MPH
Pervasive and recurrent gun violence compels health care organizations to integrate violence prevention, intervention, and recidivism reduction as critical dimensions of good trauma care.
AMA J Ethics. 2018;20(5):483-491. doi:
10.1001/journalofethics.2018.20.5.msoc2-1805.
The convening power of clinical ethics committees stems from their reputation for fairness and procedural legitimacy in addressing and resolving ethically complex cases.
AMA J Ethics. 2016;18(5):540-545. doi:
10.1001/journalofethics.2016.18.5.msoc2-1605.
Hanni Stoklosa, MD, MPH, Marti MacGibbon, CADC-II, ACRPS, and Joseph Stoklosa, MD
Clinicians diagnosing and treating potentially trafficked patients with co-occurring addiction and mental illness should guard against expressing negative biases.
AMA J Ethics. 2017;19(1):23-24. doi:
10.1001/journalofethics.2017.19.1.ecas3-1701.
The DSM-5 Task Force’s handling of the ethical controversy over the bereavement exclusion demonstrates the need for more inclusive deliberative processes.
AMA J Ethics. 2017;19(2):192-198. doi:
10.1001/journalofethics.2017.19.2.pfor2-1702.
Carrie A. Bohnert, MPA, Aaron W. Calhoun, MD, and Olivia F. Mittel, MD, MS
Research and training are needed so that physicians are able to identify human trafficking victims and refer them to appropriate trauma-informed treatment.
AMA J Ethics. 2017;19(1):35-42. doi:
10.1001/journalofethics.2017.19.1.ecas4-1701.